A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Simvastatin has demonstrated anti-tumor activity in preclinical studies via tumor cell senescence, apoptosis, and anti-angiogenesis. This phase II trial evaluated the efficacy and toxicity profile of conventional XELOX and bevacizumab chemotherapy plus simvastatin in metastatic colorectal cancer patients (MCRC). Materials and Methods Patients with MCRC received first-line XELOX in 3-week treatment cycles of intravenous xaliplatin 130 mg/m2 plus bevacizumab 7.5 mg/kg (day 1), followed by oral capecitabine 1,000 mg/m2 twice daily (day 1-14). Simvastatin 80 mg tablets were taken orally once daily every day during the period of chemotherapy. The primary endpoint was progression-free survival (PFS). Secondary endpoints were response rate, duration of response, overall survival (OS), time to progression, and toxicity. Results From January 2014 to April 2015, 60 patients were enrolled and 55 patients were evaluable for tumor response. The median follow-up duration was 30.1 months (range, 28.5 to 31.7 months). The median PFS was 10.4 months (95% confidence interval [CI], 9.6 to 11.1). The median OS of all patients was 19.0 months (95% CI, 11.9 to 26.0). The disease-control rate and overall response rate were 88.3% (95% CI, 74 to 96) and 58.3% (95% CI, 44 to 77), respectively, by intent-to-treat protocol analysis. There was one complete response and 34 partial responses. One patient experienced grade 3 creatine kinase elevation and liver enzyme elevation. Conclusion Based on the current study, the addition of 80 mg simvastatin to XELOX and bevacizumab showed comparable clinical efficacy in patients with MCRC as first-line chemotherapy and did not increase toxicity.
Abstract
Purpose Simvastatin has demonstrated anti-tumor activity in preclinical studies via tumor cell senescence, apoptosis, and anti-angiogenesis. This phase II trial evaluated the efficacy and toxicity profile of conventional XELOX and bevacizumab chemotherapy plus simvastatin in metastatic colorectal cancer patients (MCRC). Materials and Methods Patients with MCRC received first-line XELOX in 3-week treatment cycles of intravenous xaliplatin 130 mg/m2 plus bevacizumab 7.5 mg/kg (day 1), followed by oral capecitabine 1,000 mg/m2 twice daily (day 1-14). Simvastatin 80 mg tablets were taken orally once daily every day during the period of chemotherapy. The primary endpoint was progression-free survival (PFS). Secondary endpoints were response rate, duration of response, overall survival (OS), time to progression, and toxicity. Results From January 2014 to April 2015, 60 patients were enrolled and 55 patients were evaluable for tumor response. The median follow-up duration was 30.1 months (range, 28.5 to 31.7 months). The median PFS was 10.4 months (95% confidence interval [CI], 9.6 to 11.1). The median OS of all patients was 19.0 months (95% CI, 11.9 to 26.0). The disease-control rate and overall response rate were 88.3% (95% CI, 74 to 96) and 58.3% (95% CI, 44 to 77), respectively, by intent-to-treat protocol analysis. There was one complete response and 34 partial responses. One patient experienced grade 3 creatine kinase elevation and liver enzyme elevation. Conclusion Based on the current study, the addition of 80 mg simvastatin to XELOX and bevacizumab showed comparable clinical efficacy in patients with MCRC as first-line chemotherapy and did not increase toxicity.
참고문헌 (24)
- Siegel RL, "Colorectal cancer statistics, 2017", CA Cancer J Clin, 67, pp.177~193 (2017)
- Matsui T, "Bi-weekly capecitabine-oxaliplatin(XELOX)plus bevacizumab as first-line treatment of metastatic colorectal cancer : the PHOENiX Trial", Anticancer Res, 36, pp.3437~3443 (2016)
- Lee JJ, "An update on treatment advances for the firstline therapy of metastatic colorectal cancer", Cancer J, 13, pp.276~281 (2007)
- Carmeliet P., "VEGF as a key mediator of angiogenesis in cancer", Oncology, 69(Suppl 3), pp.4~10 (2005)
- Giantonio BJ, "Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin(FOLFOX4)for previously treated metastatic colorectal cancer : results from the Eastern Cooperative Oncology Group Study E3200", J Clin Oncol, 25, pp.1539~1544 (2007)
- Grothey A, "Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer : results from a large observational cohort study(BRiTE)", J Clin Oncol, 26, pp.5326~5334 (2008)
- Hurwitz H, "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer", N Engl J Med, 350, pp.2335~2342 (2004)
- Saltz LB, "Bevacizumab in combination with oxaliplatinbased chemotherapy as first-line therapy in metastatic colorectal cancer : a randomized phase III study", J Clin Oncol, 26, pp.2013~2019 (2008)
- Goldstein JL, "Regulation of the mevalonate pathway", Nature, 343, pp.425~430 (1990)
- Osmak M, "Statins and cancer : current and future prospects", Cancer Lett, 324, pp.1~12 (2012)
- Kubatka P, "Statins in oncological research : from experimental studies to clinical practice", Crit Rev Oncol Hematol, 92, pp.296~311 (2014)
- Chae YK, "Statins as anti-cancer therapy; Can we translate preclinical and epidemiologic data into clinical benefit?", Discov Med, 20, pp.413~427 (2015)
- Denoyelle C, "Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines : an in vitro study", Carcinogenesis, 22, pp.1139~1148 (2001)
- Keyomarsi K, "Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin", Cancer Res, 51, pp.3602~3609 (1991)
- Prasanna P, "Lipid metabolism as a target for brain cancer therapy : synergistic activity of lovastatin and sodium phenylacetate against human glioma cells", J Neurochem, 66, pp.710~716 (1996)
- Jakobisiak M, "Cell cycle-specific effects of lovastatin", Proc Natl Acad Sci U S A, 88, pp.3628~3632 (1991)
- Lee SJ, "Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90alpha in human colorectal cancer", Br J Cancer, 111, pp.497~505 (2014)
- Lee J, "Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin(FOLFIRI)as first-line chemotherapy in metastatic colorectal patients : a multicenter phase II study", Cancer Chemother Pharmacol, 64, pp.657~663 (2009)
- Therasse P, "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada", J Natl Cancer Inst, 92, pp.205~216 (2000)
- Negre-Aminou P, "Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types", Biochim Biophys Acta, 1345, pp.259~268 (1997)
- Pirillo A, "Simvastatin modulates the heat shock response and cytotoxicity mediated by oxidized LDL in cultured human endothelial smooth muscle cells", Biochem Biophys Res Commun, 231, pp.437~441 (1997)
- Schaefer CA, "Statins prevent oxidized low-density lipoproteinand lysophosphatidylcholine-induced proliferation of human endothelial cells", Vascul Pharmacol, 41, pp.67~73 (2004)
- Alber HF, "Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease", J Am Coll Cardiol, 39, pp.1951~1955 (2002)
- Kabbinavar FF, "Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer : results from a large treatment observational cohort study", Eur J Cancer, 48, pp.1126~1132 (2012)